Toshifumi Yokota

Department of Medical Genetics, University of Alberta Faculty of Medicine and Dentistry

Affiliated withUniversity of Alberta Faculty of Medicine and Dentistry

Research Area

Biography

Toshifumi Yokota has not added Biography.
If you are Toshifumi Yokota and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 3	Year
Publication title Cited by 23	2016
Publication title Cited by 9	2018
Publication title Cited by 7	2018

Other Publications

Article	Year
Micro-dystrophin cDNA ameliorates dystrophic phenotypes when introduced into mdx mice as a transgene. Biochemical and biophysical research communications\| PubMed ID: 12054513	2002
Alpha1-syntrophin-deficient skeletal muscle exhibits hypertrophy and aberrant formation of neuromuscular junctions during regeneration. The Journal of cell biology\| PubMed ID: 12221071	2002
Alpha1-syntrophin modulates turnover of ABCA1. The Journal of biological chemistry\| PubMed ID: 14722086	2004
Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 15608067	2005
Expansion of revertant fibers in dystrophic mdx muscles reflects activity of muscle precursor cells and serves as an index of muscle regeneration. Journal of cell science\| PubMed ID: 16757519	2006
Potential of oligonucleotide-mediated exon-skipping therapy for Duchenne muscular dystrophy. Expert opinion on biological therapy\| PubMed ID: 17555369	2007
A renaissance for antisense oligonucleotide drugs in neurology: exon skipping breaks new ground. Archives of neurology\| PubMed ID: 19139297	2009
Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs. Annals of neurology\| PubMed ID: 19288467	2009
Antisense PMO found in dystrophic dog model was effective in cells from exon 7-deleted DMD patient. PloS one\| PubMed ID: 20805873	2010
In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52-deficient mdx mouse. Molecular therapy : the journal of the American Society of Gene Therapy\| PubMed ID: 20823833	2010
The status of exon skipping as a therapeutic approach to duchenne muscular dystrophy. Molecular therapy : the journal of the American Society of Gene Therapy\| PubMed ID: 20978473	2011
Antisense oligo-mediated multiple exon skipping in a dog model of duchenne muscular dystrophy. Methods in molecular biology (Clifton, N.J.)\| PubMed ID: 21194037	2011
Restoring dystrophin expression in duchenne muscular dystrophy muscle progress in exon skipping and stop codon read through. The American journal of pathology\| PubMed ID: 21703390	2011
Pathogenic exon-trapping by SVA retrotransposon and rescue in Fukuyama muscular dystrophy. Nature\| PubMed ID: 21979053	2011
Exon skipping for nonsense mutations in Duchenne muscular dystrophy: too many mutations, too few patients? Expert opinion on biological therapy\| PubMed ID: 22650324	2012
Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 22869723	2012
Extensive and prolonged restoration of dystrophin expression with vivo-morpholino-mediated multiple exon skipping in dystrophic dogs. Nucleic acid therapeutics\| PubMed ID: 22888777	2012
Highly efficient in vivo delivery of PMO into regenerating myotubes and rescue in laminin-α2 chain-null congenital muscular dystrophy mice. Human molecular genetics\| PubMed ID: 23882132	2013
Mutation types and aging differently affect revertant fiber expansion in dystrophic mdx and mdx52 mice. PloS one\| PubMed ID: 23894429	2013
Development of multiexon skipping antisense oligonucleotide therapy for Duchenne muscular dystrophy. BioMed research international\| PubMed ID: 23984357	2013
α1-Syntrophin-deficient mice exhibit impaired muscle force recovery after osmotic shock. Muscle & nerve\| PubMed ID: 24037898	2014
Morpholino treatment improves muscle function and pathology of Pitx1 transgenic mice. Molecular therapy : the journal of the American Society of Gene Therapy\| PubMed ID: 24232919	2014
Skipping multiple exons of dystrophin transcripts using cocktail antisense oligonucleotides. Nucleic acid therapeutics\| PubMed ID: 24380394	2014
New developments in exon skipping and splice modulation therapies for neuromuscular diseases. Expert opinion on biological therapy\| PubMed ID: 24620745	2014
Antisense therapy in neurology. Journal of personalized medicine\| PubMed ID: 25562650	2013
Long-term efficacy of systemic multiexon skipping targeting dystrophin exons 45-55 with a cocktail of vivo-morpholinos in mdx52 mice. Molecular therapy. Nucleic acids\| PubMed ID: 25647512	2015
In silico screening based on predictive algorithms as a design tool for exon skipping oligonucleotides in Duchenne muscular dystrophy. PloS one\| PubMed ID: 25816009	2015
Nonmechanical Roles of Dystrophin and Associated Proteins in Exercise, Neuromuscular Junctions, and Brains. Brain sciences\| PubMed ID: 26230713	2015
Muscular Dystrophy: Disease Mechanisms and Therapies. BioMed research international\| PubMed ID: 26380274	2015
Dystrophin-deficient large animal models: translational research and exon skipping. American journal of translational research\| PubMed ID: 26396664	2015
Antisense oligonucleotide drugs for Duchenne muscular dystrophy: how far have we come and what does the future hold? Future medicinal chemistry\| PubMed ID: 26423833	2015
Deletion of exons 3-9 encompassing a mutational hot spot in the DMD gene presents an asymptomatic phenotype, indicating a target region for multiexon skipping therapy. Journal of human genetics\| PubMed ID: 27009627	2016
Current Translational Research and Murine Models For Duchenne Muscular Dystrophy. Journal of neuromuscular diseases\| PubMed ID: 27854202	2016
Impaired regenerative capacity and lower revertant fibre expansion in dystrophin-deficient mdx muscles on DBA/2 background. Scientific reports\| PubMed ID: 27924830	2016
Systemic Delivery of Morpholinos to Skip Multiple Exons in a Dog Model of Duchenne Muscular Dystrophy. Methods in molecular biology (Clifton, N.J.)\| PubMed ID: 28364245	2017
Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 28373570	2017
LNA/DNA mixmer-based antisense oligonucleotides correct alternative splicing of the SMN2 gene and restore SMN protein expression in type 1 SMA fibroblasts. Scientific reports\| PubMed ID: 28623256	2017
Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy. Molecular therapy : the journal of the American Society of Gene Therapy\| PubMed ID: 28865998	2017
Immortalized Muscle Cell Model to Test the Exon Skipping Efficacy for Duchenne Muscular Dystrophy. Journal of personalized medicine\| PubMed ID: 29035327	2017
Exon Skipping Therapy Using Phosphorodiamidate Morpholino Oligomers in the mdx52 Mouse Model of Duchenne Muscular Dystrophy. Methods in molecular biology (Clifton, N.J.)\| PubMed ID: 29067660	2018
Designing Effective Antisense Oligonucleotides for Exon Skipping. Methods in molecular biology (Clifton, N.J.)\| PubMed ID: 29067661	2018
Skipping Multiple Exons to Treat DMD-Promises and Challenges. Biomedicines\| PubMed ID: 29301272	2018